Institute of Mental Health

imh.com.sg

The Institute of Mental Health (IMH) is a 2,000-bed acute tertiary psychiatric hospital situated on a 23-hectare campus at Buangkok Green Medical Park. Set amidst serene surroundings, IMH offers a comprehensive range of psychiatric, rehabilitative and counselling services for children, adolescents, adults, and the elderly.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

news image

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More

CELL AND GENE THERAPY

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

news image

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More

INDUSTRIAL IMPACT

ABCELLERA AND RALLYBIO ANNOUNCE STRATEGIC ALLIANCE TO DISCOVER, DEVELOP, AND COMMERCIALIZE NOVEL ANTIBODY-BASED THERAPEUTICS FOR RARE DISEASES

Rallybio | December 02, 2022

news image

AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients. “It’...

Read More

INDUSTRIAL IMPACT

INVENTORS OF BIOLAYER INTERFEROMETRY TECHNOLOGY LAUNCH A NEXT GEN PLATFORM AND NOVEL BIOSENSORS

Gator Bio | September 15, 2021

news image

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...

Read More
news image

MEDTECH

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More
news image

CELL AND GENE THERAPY

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More
news image

INDUSTRIAL IMPACT

ABCELLERA AND RALLYBIO ANNOUNCE STRATEGIC ALLIANCE TO DISCOVER, DEVELOP, AND COMMERCIALIZE NOVEL ANTIBODY-BASED THERAPEUTICS FOR RARE DISEASES

Rallybio | December 02, 2022

AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients. “It’...

Read More
news image

INDUSTRIAL IMPACT

INVENTORS OF BIOLAYER INTERFEROMETRY TECHNOLOGY LAUNCH A NEXT GEN PLATFORM AND NOVEL BIOSENSORS

Gator Bio | September 15, 2021

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...

Read More